This open-label, phase 3, randomized ICTAN trial (ClinicalTrials.gov identifier: NCT01996098) investigated whether icotinib following adjuvant chemotherapy improves long-term survival outcomes compared with observation in stage II-IIIA NSCLC with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.